Tag results:

Industry & Policy News

UK First to Approve CRISPR Treatment for Diseases: What You Need to Know

[Nature] In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The approval by the Medicines and Healthcare products Regulatory Agency (MHRA) follows promising results from clinical trials that tested a one-time treatment, which is administered by intravenous infusion.

Marcus Ruscetti Receives American Cancer Society Award for Prostate Cancer Research

[UMass Chan Medical School] “What we will do with this American Cancer Society grant is try to understand why sometimes senescence is good and stops tumors from growing and other times it’s bad and leads to immune suppression,” Dr. Ruscetti said.

FRUZAQLA (Fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson

[McKesson Corporation] Biologics by McKesson has announced the US FDA approval of FRUZAQLA, an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

[Icahn School of Medicine (EurekaAlert)] The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Julie Palmer, ScD, Receives Breast Cancer Research Foundation Grant

[Boston University] Julie Palmer, ScD, co-director of the Boston University-Boston Medical Center Cancer Center, has been awarded a one-year, $589,000 Research Grant from the Breast Cancer Research Foundation for her research, “Breast Cancer Drivers in Black Women: Society to Cells.”

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase II Study of Advanced (F3) MASH Liver Disease

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced additional efficacy data for rencofilstat, its lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, hepatocellular carcinoma, and other chronic diseases.

Popular